LightDark Log in Sign up

‹ Back to screener

LALPATHLAB.NS Dr. Lal Path Labs Ltd.

Healthcare

Price history

1M 6M 1Y 3Y Max
2025-08-21 ₹1691.70
2026-08-21 ₹1890.70
Change over window +11.76%

Price is the daily close from stored Kite history. The other metrics pair that daily price with the company's periodic filings — each fundamental (revenue, EPS, equity…) is held flat at its latest filed value between annual filings, so a ratio steps at each filing and moves daily only through its price term. A metric with no input on file for this company (e.g. EV/EBITDA for a bank, which has no EBIT) is shown as unavailable, never guessed. Share-count-based metrics use the latest diluted share count against split/bonus-adjusted prices.

Technical indicators

ℹ These reflect only the stock's recent price and volume behavior — not the company's fundamentals — and are not a recommendation to buy or sell. Standard published parameters are used throughout (see each chart's own label); a company with too little stored price history for a given indicator's lookback window shows that plainly below rather than a garbage or misleading value.

MACD (12,26,9), Stochastic Oscillator (14,3) and Money Flow Index (14-day) each carry their own published reference lines/bands (20/80 for the oscillator readings) where one is standard. ADX includes +DI/-DI for direction alongside trend strength; a dashed line marks the commonly published 25 "trending market" reading. ATR is shown in raw rupees here; the price/volume preset screen (below, and on the Screener page) reports it as a % of price so it's comparable across stocks at different price levels. Computed from the same stored daily OHLCV history as the price chart above — no new data source.

Delivery volume

Latest (2026-08-28) 60.3%
Trailing 20-day average 58.2%
Date Traded Qty Delivery Qty Delivery %
2026-08-28 90724 54710 60.30%
2026-08-27 87929 49758 56.59%
2026-08-26 134265 70012 52.14%
2026-08-25 194732 103917 53.36%
2026-08-24 146775 84191 57.36%
2026-08-21 99702 47892 48.04%
2026-08-20 308167 178058 57.78%
2026-08-19 156564 108777 69.48%
2026-08-18 211640 114212 53.97%
2026-08-17 134988 56874 42.13%
2026-08-14 229786 125395 54.57%
2026-08-13 205127 140667 68.58%
2026-08-12 351481 226953 64.57%
2026-08-11 198678 133360 67.12%
2026-08-10 290743 146945 50.54%
2026-08-07 158460 99318 62.68%
2026-08-06 427191 254503 59.58%
2026-08-05 318039 185971 58.47%
2026-08-04 500180 297524 59.48%
2026-08-03 718505 482379 67.14%

Delivery quantity/percentage from the NSE bhavcopy (DELIV_QTY/DELIV_PER) — the share of that day's traded volume that actually settled into a demat account, rather than being squared off intraday. A higher delivery percentage is commonly read as genuine accumulation/distribution rather than speculative same-day trading; this describes recent trading PATTERN, not the company itself, and is not a recommendation to buy or sell. A blank cell is a day NSE itself published no figure for, never a zero. Run python manage.py refresh_delivery_volumes --tickers LALPATHLAB.NS to fetch more history.

Insider trading activity

Disclosed Person Category Type Mode Quantity Value (₹) Resulting stake
01 May 2026 Dr. Lal PathLabs Employees Welfare Trust Other Buy ESOP 82750 94434300 0.39% XBRL
31 Mar 2026 Rahul Sharma Director Sell Market Sale 1000 1302700 0.02% XBRL
24 Feb 2026 Dr. Lal PathLabs Employees Welfare Trust Other Sell ESOP 2024 1541996 0.35% XBRL
24 Feb 2026 Abhishek Aggarwal Employees/Designated Employees Buy ESOP 1500 1539376 0.00% XBRL
19 Feb 2026 Dr. Lal PathLabs Employees Welfare Trust Other Sell ESOP 1876 670132 0.35% XBRL
11 Feb 2026 Jitender Sharma Employees/Designated Employees Pledge Pledge Creation 2470 3568903 0.00% XBRL
04 Feb 2026 Rahul Sharma Director Buy ESOP 4000 622600 0.02% XBRL
31 Dec 2025 Rahul Sharma Director Sell Market Sale 2500 3657000 0.01% XBRL
31 Dec 2025 Sanjay Kulshreshtha Employees/Designated Employees Buy ESOP 250 2500 0.00% XBRL
31 Dec 2025 Sanjay Kulshreshtha Employees/Designated Employees Buy ESOP 424 2120 0.00% XBRL
31 Dec 2025 Gaurav Sharma Employees/Designated Employees Buy ESOP 2500 2535015 0.00% XBRL
31 Dec 2025 Dr. Lal PathLabs Employees Welfare Trust Other Sell ESOP 4424 2544635 0.35% XBRL
31 Dec 2025 Abhishek Aggarwal Employees/Designated Employees Sell Market Sale 1750 2542750 0.00% XBRL
17 Dec 2025 Dr. Lal PathLabs Employees Welfare Trust Other Sell ESOP 4350 1003526 0.35% XBRL
17 Dec 2025 Ved Prakash Goel Key Managerial Personnel Buy ESOP 450 4500 0.02% XBRL
17 Dec 2025 Dr. Seema Narang Kochhar Employees/Designated Employees Buy ESOP 750 7500 0.02% XBRL
17 Dec 2025 Manoj Kumar Garg Employees/Designated Employees Buy ESOP 2500 25000 0.03% XBRL
05 Dec 2025 Dr. Lal PathLabs Employees Welfare Trust Other Sell ESOP 686 486873 0.35% XBRL
13 Nov 2025 Dr. Lal PathLabs Employees Welfare Trust Other Sell ESOP 3200 32000 0.36% XBRL
13 Nov 2025 Ved Prakash Goel Key Managerial Personnel Buy ESOP 3200 32000 0.02% XBRL

SEBI PIT (Prohibition of Insider Trading) Regulation 7 disclosures — designated persons (promoters, directors, KMPs, and their immediate relatives) reporting their own dealing in the company's securities, as NSE publishes them. Distinct from the SAST (Regulation 29 substantial-acquisition) filings on the market-wide SAST activity page. Public record only — this is descriptive disclosure data, not a signal, and is not a recommendation to buy or sell. Run python manage.py refresh_insider_trades --tickers LALPATHLAB.NS to fetch more.

Ratios as of FY2025-26 (Annual) · Price ₹1894.20 INR (live) · fetched 2026-08-23 21:45 price stale

Extract this company (financials + ratios + citations): CSV · XLSX

Full statements: Profit & Loss · Balance Sheet · Cash Flow · Compare with 46 peers in Healthcare · Trace Score

Ratios

P/E
62.89
P/E = Price / EPS
Source trace
P/E = Price / (ProfitOrLossAttributableToOwnersOfParent / PaidUpValueOfEquityShareCapital ÷ FaceValueOfEquityShareCapital) → ₹1,894.20 / (₹5,048,000,000 / 167,600,000 shares) = ₹1,894.20 / ₹30.12 EPS
FY2025-26 · Annual filing
ROE
20.13%
ROE = Net Income / Shareholder Equity
Source trace
ROE = ProfitOrLossAttributableToOwnersOfParent / EquityAttributableToOwnersOfParent → ₹5,048,000,000 / ₹25,082,000,000 = 20.13%
FY2025-26 · Annual filing
Debt/Equity
0.00
Debt/Equity = Total Debt / Shareholder Equity
Source trace
Debt/Equity = BorrowingsCurrent + BorrowingsNoncurrent / EquityAttributableToOwnersOfParent → ₹0 / ₹25,082,000,000 = 0.00
FY2025-26 · Annual filing
Current Ratio
3.48
Current Ratio = Current Assets / Current Liabilities
Source trace
Current Ratio = CurrentAssets / CurrentLiabilities → ₹15,666,000,000 / ₹4,507,000,000 = 3.48
FY2025-26 · Annual filing
ROCE
28.79%
ROCE = EBIT / (Shareholder Equity + Total Debt)
Source trace
ROCE = ProfitBeforeExceptionalItemsAndTax + FinanceCosts / (EquityAttributableToOwnersOfParent + BorrowingsCurrent + BorrowingsNoncurrent) → ₹7,220,000,000 / (₹25,082,000,000 + ₹0) = 28.79%
FY2025-26 · Annual filing
Dividend Yield
0.70%
Dividend Yield = (Dividends Paid / Diluted Shares Outstanding) / Price

This is cash paid during the fiscal year, not a per-share rate declared for it (no such element exists in the filing data) — timing can straddle interim/final dividends across years, and pre-FY2020-21 figures may include the since-abolished Dividend Distribution Tax, reading higher than later years for that reason alone.

Source trace
Dividend Yield = (|DividendsPaidClassifiedAsFinancingActivities| / PaidUpValueOfEquityShareCapital ÷ FaceValueOfEquityShareCapital) / Price → (₹2,226,000,000 / 167,600,000 shares) / ₹1,894.20 = ₹13.28 / ₹1,894.20
FY2025-26 · Annual filing

Growth & earnings trend

Revenue & Profit CAGR

Revenue (3y, 3.0y actual) 11.1%
Net Profit (3y) 28.3%
Revenue (5y, 3.0y actual) 11.1%
Net Profit (5y) 28.3%
Revenue (10y, 3.0y actual) 11.1%
Net Profit (10y) 28.3%

Operating Margin Trend

Expanding

FY2022-23 18.9%
FY2023-24 24.0%
FY2024-25 26.3%
FY2025-26 26.1%

ROCE Trajectory

FY2022-23 19.7%
FY2023-24 27.2%
FY2024-25 29.3%
FY2025-26 28.4%

Earnings Quality

No persistent gap detected

Net Profit CAGR 28.31% vs CFO CAGR 11.71% over 3.0y (2023-03-31 → 2026-03-31); most recent year: Net Profit +3.63% vs CFO +11.76%

Sector-Relative Percentile (Healthcare)

ROE 87th
ROCE 91th
Debt/Equity 100th
P/E 41th

Quarterly trend

Revenue Net Profit Net Profit (loss quarter)
Metric (to shareholders basis) Q4 FY2023-24 Q1 FY2024-25 Q2 FY2024-25 Q3 FY2024-25 Q4 FY2024-25 Q1 FY2025-26 Q2 FY2025-26 Q3 FY2025-26 Q4 FY2025-26 Q1 FY2026-27 Source
Revenue ₹5.45 Bn ₹6.02 Bn ₹6.60 Bn ₹5.97 Bn ₹6.03 Bn ₹6.70 Bn ₹7.31 Bn ₹6.60 Bn ₹7.03 Bn ₹7.98 Bn RevenueFromOperations
Net Profit ₹0.84 Bn incl. minority ₹0.86 Bn ₹1.06 Bn incl. minority ₹1.08 Bn ₹1.29 Bn incl. minority ₹1.31 Bn ₹0.97 Bn incl. minority ₹0.98 Bn ₹1.55 Bn incl. minority ₹1.55 Bn ₹1.32 Bn incl. minority ₹1.34 Bn ₹1.51 Bn incl. minority ₹1.52 Bn ₹0.91 Bn incl. minority ₹0.91 Bn ₹1.31 Bn incl. minority ₹1.32 Bn ₹1.70 Bn incl. minority ₹1.71 Bn ProfitOrLossAttributableToOwnersOfParent

Primary figures are Revenue from Operations and Net Profit attributable to shareholders — the basis the ratios use. Where they differ, the companion Gross revenue (incl. inter-segment) and incl. minority net profit (the totals a news headline usually quotes) are shown beneath, each traceable to its own XBRL element. Quarters shown are however many are actually stored (up to 10) — run python manage.py refresh_quarterly_trend --tickers LALPATHLAB.NS to fetch more.

Source document — income statement (FY2025-26, raw filing line items)

View original filing on NSE ↗ NSE's own filing document, opened in a new tab — StockProof links to it, never stores a copy.

ProfitOrLossAttributableToOwnersOfParent5048000000.0
PaidUpValueOfEquityShareCapital ÷ FaceValueOfEquityShareCapital167600000.0
Source document — balance sheet (FY2025-26, raw filing line items)

View original filing on NSE ↗ NSE's own filing document, opened in a new tab — StockProof links to it, never stores a copy.

CurrentAssets15666000000.0
CurrentLiabilities4507000000.0
EquityAttributableToOwnersOfParent25082000000.0
BorrowingsCurrent + BorrowingsNoncurrent—

My notes